A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma or Other Brain Cancers After Failure of Radiation Therapy and Temozolomide

Trial Profile

A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma or Other Brain Cancers After Failure of Radiation Therapy and Temozolomide

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms KING
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, clinical data from this study was highlighted in an oral presentation at the 2017 WFNOS meeting by Andrew Lassman, MD, Columbia University Medical Center.
    • 04 May 2017 According to a Karyopharm Therapeutics media release, data will be presented at the 2017 World Federation of Neuro-Oncology Societies (WFNOS).
    • 31 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top